Solution-Phase Peptide Coupling for GLP-1 Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing GLP-1 and GLP-2 peptides, such as Liraglutide, Semaglutide, and Teduglutide, face challenges including low yields, purification difficulties, and the use of toxic reagents, particularly in the incorporation of Lys(20) and the introduction of Pal-Glu or C18-Glu-PEG2 units.
Innovation Solution
A process involving the solution-phase coupling of peptide fragments, where the carboxy terminal amino acid of one fragment reacts with the amino terminal amino acid of another, allowing for the early introduction of Pal-Glu or C18-Glu-PEG2 units on the Lys side chain, thereby reducing racemization and improving yields.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If solid-phase synthesis methods are used for GLP-1 and GLP-2 peptides, then the synthesis process is established, but racemization occurs and yields are low
Solution Approach 1:
The patent changes the fundamental parameter of the synthesis environment from solid-phase to solution-phase. This parameter change allows for milder reaction conditions that prevent racemization while maintaining efficient peptide bond formation, thereby resolving the contradiction between manufacturing precision (racemization control) and productivity (yield).
Solution Approach 2:
The patent employs HBTU (O-(6-(dimethylamino)-N-methyl-6-oxo-hexyl)uronium tetrafluoroborate) as an intermediary coupling agent that mediates the peptide bond formation in solution-phase synthesis. This intermediary enables efficient coupling without requiring harsh conditions that would cause racemization, thus improving both precision and productivity.
2Ease of manufacture
If conventional synthesis methods are used, then the basic peptide structure can be formed, but purification is difficult and toxic reagents are required
Solution Approach 1:
The patent employs temporary protecting groups (such as Fmoc, Boc, Cbz) that can be selectively removed under mild conditions. These disposable protecting groups enable the synthesis process to proceed without requiring toxic reagents, and their removable nature simplifies purification by allowing selective deprotection and purification steps.
Solution Approach 2:
The solution-phase synthesis method changes the reaction parameters to use milder, non-toxic reagents compared to conventional solid-phase methods. This parameter change in the synthesis environment eliminates the need for toxic substances while maintaining synthesis efficiency, thereby improving ease of manufacture through simpler purification processes.
3Productivity
If Lys(20) incorporation is performed using conventional methods, then the peptide chain can be assembled, but the process becomes complex and low yielding
Solution Approach 1:
The patent segments the peptide synthesis into manageable solution-phase reactions rather than a single complex solid-phase process. By dividing the synthesis into discrete coupling steps with controlled conditions, the incorporation of Lys(20) becomes less complex and more controllable, improving yield while reducing overall process complexity.
Solution Approach 2:
The patent uses specific coupling intermediaries and protecting group strategies that simplify the Lys(20) incorporation step. The solution-phase environment allows for cleaner reactions with fewer side products, reducing the complexity of the synthesis process while maintaining high yield for the Lys(20) containing peptides.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in significantly lower racemization rates (<10%) compared to solid-phase methods, leading to improved yields and purity of GLP-1 and GLP-2 peptides, and is suitable for industrial scale-up without the use of toxic reagents.
Implementation Method 1
The method is based on the condensation of two or more fragments in solution
Data Source
AI summary
A process for preparing a GLP-1 or GLP-2 peptide, said process comprising coupling in solution at least a first fragment and at least a second fragment, wherein the coupling comprises reacting the carboxy terminal amino acid of the first fragment with the amino terminal amino acid of the second fragment, and wherein the carboxy terminal amino acid of the first fragment is other than a Gly residue